Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026. In an interview with Bloomberg TV ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Regarding the guidance approach, the CEO noted, "The scale of this business ... the 3Q results and guidance update." Price Action: LLY stock is up 0.59% at $749.28 at the last check on Wednesday.

Throughout the week, the host covered JPMorgan’s healthcare conference, during which he also conducted an interview of Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks. Despite the fact that ...

Also Read: Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall Omvoh works ... of additional treatment (two ...

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected results, and economists expect annual inflation to have risen in December.

Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...